Mechanism of Action of Sulindac
Sulindac’s exact mechanism of action is unknown. Its anti-inflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
or
Sulindac is a prodrug that is converted to an active sulfide metabolite, which is responsible for most of the pharmacologic activity. The active metabolite of sulindac competitively inhibits both cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, by blocking arachidonate binding resulting in analgesic, antipyretic, and anti-inflammatory pharmacologic effects. The parent drug has a minimal inhibitory effect on COX; the sulfide metabolite is 500 times more potent. The enzymes COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin G2 (PGG2), the first step of the synthesis prostaglandins and thromboxanes that are involved in rapid physiological responses. COX isoenzymes are also responsible for a peroxidase reaction, which is not affected by NSAIDs. In addition, NSAIDs do not suppress leukotriene synthesis by lipoxygenase pathways. COX-1 is constitutively expressed in almost all tissues, while COX-2 appears to only be constitutively expressed in the brain, kidney, bones, reproductive organs, and some neoplasms (e.g., colon and prostate cancers). COX-1 is responsible for prostaglandin synthesis in response to stimulation by circulating hormones, as well as maintenance of normal renal function, gastric mucosal integrity, and hemostasis. However, COX-2 is inducible in many cells in response to certain mediators of inflammation (e.g., interleukin-1, tumor necrosis factor, lipopolysaccharide, mitogens, and reactive oxygen intermediates).
FDA Level
- Anti-inflammatory Activity – The anti-inflammatory mechanism of sulindac is due to decreased prostaglandin synthesis via inhibition of COX-1 and COX-2. It appears that the anti-inflammatory effects may be primarily due to inhibition of the COX-2 isoenzyme. However, COX-1 is expressed at some sites of inflammation. COX-1 is expressed in the joints of rheumatoid arthritis or osteoarthritis patients, especially the synovial lining, and it is the primary enzyme of prostaglandin synthesis in human bursitis. Sulindac is considered a non-selective NSAID; however, it is highly selective for the COX-1 isoenzyme.
- Analgesic Activity – Sulindac is effective in cases where inflammation has caused the sensitivity of pain receptors (hyperalgesia). It appears prostaglandins, specifically prostaglandins E and F, are responsible for sensitizing the pain receptors; therefore, sulindac has an indirect analgesic effect by inhibiting the production of further prostaglandins and does not directly affect hyperalgesia or the pain threshold.
- Antipyretic Activity – Sulindac promotes a return to a normal body temperature set point in the hypothalamus by suppressing the synthesis of prostaglandins, specifically PGE2, in circumventricular organs in and near the hypothalamus. Sulindac may mask fever in some patients, especially with high or chronic dosing.
- GI Effects – Gastrointestinal side effects of sulindac are primarily contributed to COX-1 inhibition; however, the potential role of COX-2 inhibition in the GI tract has not been fully elucidated.
- Platelet Effects – The inhibition of platelet aggregation seen with sulindac is due to a dose-dependent inhibition of COX-1 in platelets leading to decreased levels of platelet thromboxane A2 and an increase in bleeding time (see Adverse Reactions). The inhibition of platelet aggregation is reversible within 24 hours of discontinuation of sulindac. This differs from aspirin, which irreversibly binds to COX-1 in platelets inhibiting this enzyme for the life of the cell.
- Renal Effects: In the kidney, prostaglandins, produced by both COX-1 and COX-2, are important regulators of sodium and water reabsorption through PGE2 and of renal function and hemodynamics via PGI2 in response to vasoconstrictive factors (e.g., endothelin-1, a factor that increases peripheral vascular resistance) and through effects on the renin-angiotensin system. In conditions where renal blood flow is dependent upon prostaglandin synthesis, administration of NSAIDs can result in significant decreases in renal blood flow leading to acute renal failure. In addition, alterations in sodium and water reabsorption may worsen increased blood pressure, which can be significant in selected individuals.
Sulindac Indications
For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis
- Ankylosing Spondylitis
- Tendonitis
- Rheumatoid arthritis
- Osteoarthritis
- Acute and chronic rheumatoid arthritis,
- Mild to moderate pain associated with musculotendinous trauma
- sprains and strains
- Postpartum pain.
- Treatment of some pain, especially nerve pain such as
- Sciatica,
- Postherpetic neuralgia
- Referred pain for radiculopathy.
- Pauciarticular juvenile rheumatoid arthritis
- Polyarticular juvenile rheumatoid arthritis, chronic or unspecified
- Frozen shoulder
- Pain with itching,
- Tendonitis
- Bursitis
Sulindac Contra-Indications
- Systemic mastocytosis
- Increased risk of bleeding due to a clotting disorder
- Alcoholism
- High blood pressure
- Chronic heart failure
- Disease of the heart and blood vessels
- Stroke
- Ulcer from stomach acid
- Stomach or intestinal ulcer
- Liver problems
- Bleeding of the stomach or intestines
- Kidney stone
- Systemic lupus erythematosus
- Visible water retention
- Pregnancy
- A mother who is producing milk and breastfeeding
- A rupture in the wall of the stomach or intestine
- Increased cardiovascular event risk
- Time immediately after coronary bypass surgery
- chronic kidney disease stage 4 (severe
- A mother who is producing milk and breastfeeding
Dosages of Sulindac
Strengths: 150 mg; 200 mg
Rheumatoid Arthritis
- Initial dose: 150 mg orally twice a day
- Maximum dose: 400 mg orally per day
Osteoarthritis
- Initial dose: 150 mg orally twice a day
- Maximum dose: 400 mg orally per day
Ankylosing Spondylitis
- Initial dose: 150 mg orally twice a day
- Maximum dose: 400 mg orally per day
Acute Gout
- Initial dose: 200 mg orally twice a day
- Maximum dose: 400 mg orally per day
- Duration of therapy: 7 days is usually adequate
Bursitis
- Initial dose: 200 mg orally twice a day
- Maximum dose: 400 mg orally per day
- Duration of therapy: 7 to 14 days is usually adequate
Tendonitis
- Initial dose: 200 mg orally twice a day
- Maximum dose: 400 mg orally per day
- Duration of therapy: 7 to 14 days is usually adequate
Side Effects of Sulindac
The common
- stomach pain
- abdominal or stomach pain, cramping, or burning (severe)
- bloody or black, tarry stools
- blurred vision or any change in vision
- chest pain
- allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
- convulsions (seizures)
- fast or irregular breathing
- fast, irregular heartbeat or pulse
- indigestion
- nausea, vomiting
- diarrhea
More common
- Acid or sour stomach
- constipation
- headache
- heartburn
- nausea or vomiting
- skin rash
- stomach pain
- constipation
- gas
- rash
Less common
- Excess air or gas in the stomach or intestines
- itching skin
- passing gas
- stomach cramps
- swelling
- weight loss
- diarrhea
- indigestion or heartburn
- nausea
- dizziness
- headache
- itching or rash
Rare
- Anxiety
- change in vision
- seizures
- abnormal or fast heart rate
- weight loss
- chest pain or tightness
- confusion
- cough
- Agitation
- arm, back, or jaw pain
- blurred vision
- chest pain or discomfort
- convulsions
- extra heartbeats
- hallucinations
- headache
- irritability
- muscle pain or cramps
- pale or yellowed skin, dark colored urine, fever, confusion or weakness;
- jaundice (yellowing of the skin or eyes);
- sore throat, and headache with a severe blistering peeling, and red skin rash;
- swelling, rapid weight gain, feeling short of breath (even with mild exertion); or
- increased thirst, loss of appetite, urinating less than usual or not at all.
Drug Interactions of Sulindac
Sulindac may interact with following drugs, supplements & may change the efficacy of drugs
- aminoglycoside antibiotics (e.g., amikacin, gentamicin, tobramycin)
- angiotensin-converting enzyme (ACE) inhibitors (e.g., ramipril, enalapril, captopril, quinapril)
- angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan)
- “azole” antifungals (e.g., itraconazole, ketoconazole, voriconazole)
- beta-adrenergic blockers (e.g., atenolol, propranolol, sotalol)
- bisphosphonates (e.g., alendronate, etidronate)
- carbamazepine
- celecoxib
- cilostazol
- clopidogrel
- cyclosporine
- dabigatran
- dasatinib
- diuretics (water pills; e.g., furosemide, hydrochlorothiazide, triamterene)
- fluvastatin
- haloperidol
- heparin
- ibrutinib
- methotrexate
- multivitamins (with vitamins A, E) with or without minerals
- nilotinib
- non-steroidal anti-inflammatory medications (NSAIDs; e.g., diclofenac, ibuprofen, naproxen)
- omega-3 fatty acids
- omeprazole
- oral corticosteroids (e.g., dexamethasone, hydrocortisone, prednisone)
- pentoxifylline
- phenobarbital
- phenytoin
- quinolone antibiotics (e.g., ciprofloxacin, norfloxacin, ofloxacin)
- selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, duloxetine, fluoxetine, paroxetine, sertraline)
- serotonin/norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine, venlafaxine)
- sulfasalazine
- tricyclic antidepressants (e.g., amitriptyline, clomipramine, desipramine, trimipramine
Pregnancy & Lactation of Sulindac
Sulindac falls into category C before the 30th week of pregnancy, and category D after the 30th week.
Pregnancy
Lactation
Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if sulindac is excreted in human breast milk or if it will harm your nursing baby.
References
About the author